Table 6.
First author | ADC-value (× 10−3 mm2/s) pCR versus non-pCRa |
Reported/chosen ADC threshold for pCR (× 10−3 mm2/s) | ROC AUC (95% CI) | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) |
---|---|---|---|---|---|---|---|
Minarikova [59] | 0.87 ± 0.12 versus 0.96 ± 0.23 p = 0.287 | 0.633 | |||||
Shin [26] | 0.83 (0.77, 0.87) versus 0.97 (0.82, 1.10) p = 0.014 | 0.92 | 0.75 (0.58, 0.88) | 82 | 65 | ||
Fangberget [65]b | 1.1 versus 1.1 p = 0.693 | 0.80 | |||||
Woodhams [64]c | pCR as in full-text (excl. DCIS) | 0.55 | |||||
0.81 ± 0.15 versus 0.85 ± 0.19 p = 0.64 | 0.52 | ||||||
pCR incl. DCIS: 0.85 ± 0.18 versus 0.85 ± 0.19 p = 0.82 | |||||||
Bufi [17]d | Overall: 1.132 versus 1.092 p = 0.23 | Overall: 0.975 | Overall: 0.587 | ||||
Luminal: 1.157 versus 1.077 p = 0.59 | Luminal: 0.832 | Luminal: 0.588 | |||||
Hybrid: 1.036 versus 1.079 p = 0.53 | Hybrid: 0.959 | Hybrid: 0.567 | |||||
TN: 1.034 versus 1.114 p = 0.06 | TN: 0.995 | TN: 0.766 | |||||
HER2+: 1.101 versus 1.232 p = 0.05 | HER2+: 0.971 | HER2+: 0.813 | |||||
Pereira [18] | Overall: 0.832 ± 0.198 versus 0.853 ± 0.171 p = 0.882 | ||||||
Luminal B: 0.755 (0.596–1.035) versus 0.802 (0.483–1.090) p = 0.359 | |||||||
TN: 0.857 (0.448–1.330) versus 1.02 (0.739–1.390) p = 0.070 | |||||||
HER2: 0.826 (0.651–1.140) versus 0.847 (0.772–0.949) p = 0.522 | |||||||
Santamaria [27] | 1.025 ± 0.153 versus 1.072 ± 0.231 p = 0.549 | ||||||
Li [44] | 1.22 | 0.72 | 93 | 52 | 50 | ||
Tozaki [40]e | 0.41 versus 0.64 (range 0.46–0.83) | 0.45 | – | 100 | 100 | ||
Che [19]f (IVIM- > D) | 0.92 (0.77, 0.95) versus 0.83 (0.75, 0.92) p = 0.323 | 0.874 | 0.600 (0.424–0.759) | 69.2 (38.6–90.9) | 65.2 (42.7–83.6) | 52.9 (28.5–76.1) | 78.9 (53.9–93.0) |
Kim [53]g | 1.13 (1.01–1.25) versus 1.23 (1.12–1.41) → ADC | ||||||
1.10 (1.01–1.22) versus 1.22 (1.10–1.49) → D | |||||||
Yuan [22] | Luminal A: 0.556 | ||||||
Luminal B: 0.538 | |||||||
Basal-like: 0.534 | |||||||
HER2-Enr.: 0.601 | |||||||
Partridge [23] | 1.08 ± 0.16 versus 1.08 ± 0.22 | ||||||
Liu [16] | Luminal A: 1.01 ± 0.12 versus 1.06 ± 0.07 p = 0.293 | ||||||
Luminal B: 1.01 ± 0.16 versus 1.07 ± 0.08 p = 0.070 | |||||||
HER2-enriched: 1.05 ± 0.11 versus 1.14 ± 0.07 p = 0.098 | |||||||
Triple-negative: 1.04 ± 0.08 versus 1.22 ± 0.08 p < 0.001 | |||||||
Bedair [20] | 0.92 ± 0.03 versus 1.20 ± 0.02 p < 0.01 → ADC | 1.012 | 0.749 | 81 | 67 | ||
0.93 ± 0.04 versus 1.25 ± 0.03 p < 0.01 → DDC | 1.141 | 0.756 | 81 | 72 | |||
0.85 ± 0.05 versus 1.02 ± 0.05 p = 0.02 → D | 0.838 | 0.644 | 60 | 47 | |||
Other model based measures: 0.81 ± 0.02 versus 0.84 ± 0.02 p = 0.07 → α (a.u.) | 0.967 | 0.641 | 71 | 53 | |||
Zhang [24] | 1 ± 0.2 versus 1 ± 0.2 p = 0.645 |
ADC apparent diffusion coefficient, CI confidence interval, D true diffusivity, DCIS ductal carcinoma in situ, DDC distributed diffusion coefficient, HER2 human epidermal growth factor receptor 2, f perfusion fraction, ROC AUC area under the receiver operating characteristic curve, NPV negative predictive value, pCR pathologic complete response, PPV positive predictive value, TN triple negative
aMean ADC-value ± SD with the exception of Che et al. [19]: median ADC and the interquartile range
b31 MRI at pre NAC and after 4 cycles 27 MRI’s
cMean and SD calculated by data extraction within the supplementary material, rounded by two decimals, p value calculated with independent samples Mann–Whitney U test, and AUC-ROC in SPSS
dHybrid tumors: luminal tumors with HER2+; TN: triple negative; data from the HER2+ group represents the HER2-enriched tumors in this case
eThreshold can be chosen based on ADC-value of the pCR case, resulting in 100% sensitivity and specificity
fD is the true diffusion coefficient in IVIM
gMiller and Payne grade 4 included as good responders